Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from BriaCell Therapeutics ( (TSE:BCT) ) is now available.
BriaCell Therapeutics announced a proposed public offering of common shares, subject to market conditions, with ThinkEquity acting as the sole placement agent. The proceeds are intended for working capital, corporate purposes, and advancing business objectives, potentially impacting the company’s operational capabilities and market positioning.
More about BriaCell Therapeutics
BriaCell Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care.
YTD Price Performance: -40.49%
Average Trading Volume: 5,412
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$21.31M
See more insights into BCT stock on TipRanks’ Stock Analysis page.